Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 77,862
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12576135 | Compositions and methods for anti-TnMUC1 gold CAR t-cells | 🖼🧊📄§ | 2026-03-17 | 2042-09-21 | 0 | 31 |
| 12576145 | Crimean-Congo hemorrhagic fever virus M-segment nucleic acid vaccine and methods of use and production | 🖼🧊📄§ | 2026-03-17 | 2041-09-30 | 0 | 31 |
| 12576146 | Method for producing reassortant influenza viruses | 🖼🧊📄§ | 2026-03-17 | 2040-11-18 | 0 | 31 |
| 12576144 | Vaccines against Powassan virus, and methods of using same | 🖼🧊📄§ | 2026-03-17 | 2039-12-20 | 0 | 31 |
| 12576142 | Universal donor cells and related methods | 🖼🧊📄§ | 2026-03-17 | 2043-09-21 | 0 | 31 |
| 12576147 | Recombinant proteins with CD40 activating properties | 🖼🧊📄§ | 2026-03-17 | 2040-03-26 | 0 | 31 |
| 12576150 | CD4+ T cells expressing IL-10 and chimeric antigen receptors and uses thereof | 🖼🧊📄§ | 2026-03-17 | 2045-02-26 | 0 | 31 |
| 12576148 | Engineered immune effector cells for cancer immunotherapy that are resistant to fratricide by virtue of having genetically modified surface antigens | 🖼🧊📄§ | 2026-03-17 | 2044-01-31 | 0 | 31 |
| 12576151 | Fratricide resistant modified immune cells and methods of using the same | 🖼🧊📄§ | 2026-03-17 | 2041-09-24 | 0 | 31 |
| 12576155 | Senolytic and antiinflammatory prodrugs and methods of use thereof | 🖼🧊📄§ | 2026-03-17 | 2040-09-24 | 0 | 31 |
| 12576152 | Topical composition | 🖼🧊📄§ | 2026-03-17 | 2045-06-27 | 0 | 31 |
| 12576160 | Bispecific nanoparticle systems for targeting cancer cells | 🖼🧊📄§ | 2026-03-17 | 2042-05-06 | 0 | 31 |
| 12576157 | Peptide saporin conjugate for the treatment of cancer | 🖼🧊📄§ | 2026-03-17 | 2043-07-14 | 0 | 31 |
| 12576156 | Compound comprising self-immolative group and ligand-drug conjugate comprising same | 🖼🧊📄§ | 2026-03-17 | 2044-11-22 | 0 | 31 |
| 12576163 | Fluorescent contrast agent with targeting function, and preparation method and use thereof | 🖼🧊📄§ | 2026-03-17 | 2042-04-29 | 0 | 31 |
| 12576162 | Cell penetrating peptides and uses thereof | 🖼🧊📄§ | 2026-03-17 | 2042-05-27 | 0 | 31 |
| 12576169 | Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof | 🖼🧊📄§ | 2026-03-17 | 2040-01-29 | 0 | 31 |
| 12576167 | Gadolinium-based compound, method for producing same, and MRI contrast agent containing same | 🖼🧊📄§ | 2026-03-17 | 2041-01-22 | 0 | 31 |
| 12576165 | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors | 🖼🧊📄§ | 2026-03-17 | 2045-09-25 | 0 | 31 |
| 12576168 | Peptide PET/SPECT probes specific to oncoproteins in tumor extracellular matrix | 🖼🧊📄§ | 2026-03-17 | 2040-01-17 | 0 | 31 |
| 12576170 | Rk polypeptide radiopharmaceutical targeting HER2 and preparation method thereof | 🖼🧊📄§ | 2026-03-17 | 2040-05-22 | 0 | 31 |
| 12576178 | Apparatus for processing artificial tooth with disinfection and sterilization function | 🖼🧊📄§ | 2026-03-17 | 2042-11-24 | 0 | 31 |
| 12576201 | Methods for isolating umbilical cord blood plasma products, tissue and cellular exosomes, and compositions and methods of use thereof | 🖼🧊📄§ | 2026-03-17 | 2040-11-25 | 0 | 31 |
| 12576115 | Bacterial compositions for treating and preventing halitosis | 🖼🧊📄§ | 2026-03-17 | 2044-09-13 | 0 | 31 |
| 12576116 | Use of probiotics in the treatment and/or prevention of atopic dermatitis | 🖼🧊📄§ | 2026-03-17 | 2037-07-18 | 0 | 31 |
| 12576117 | Antiviral agent | 🖼🧊📄§ | 2026-03-17 | 2041-05-28 | 0 | 31 |
| 12576111 | Application of BMSC-exos in treating PD | 🖼🧊📄§ | 2026-03-17 | 2042-10-19 | 0 | 31 |
| 12576113 | Rotator cuff therapy using muscle fiber fragments | 🖼🧊📄§ | 2026-03-17 | 2040-10-26 | 0 | 31 |
| 12576112 | Inhibition of TNF-alpha by fibroblasts and fibroblast exosomes | 🖼🧊📄§ | 2026-03-17 | 2040-12-22 | 0 | 31 |
| 12576107 | Methods of treating chronic inflammatory diseases | 🖼🧊📄§ | 2026-03-17 | 2043-09-11 | 0 | 31 |
| 12576110 | Methods and compositions for reconstituting microglia | 🖼🧊📄§ | 2026-03-17 | 2040-08-06 | 0 | 31 |
| 12576108 | Compositions comprising hyper harmonized hydroxyl modified fullerene substances | 🖼🧊📄§ | 2026-03-17 | 2039-12-02 | 0 | 31 |
| 12576109 | Allogeneic human plasma and platelet derived products and uses thereof | 🖼🧊📄§ | 2026-03-17 | 2045-04-30 | 0 | 31 |
| 12576105 | Compositions for treating joint or connective tissue disease comprising dextran or poloxamer | 🖼🧊📄§ | 2026-03-17 | 2043-10-05 | 0 | 31 |
| 12576099 | Ribose-modified cap analog and use thereof | 🖼🧊📄§ | 2026-03-17 | 2045-02-28 | 0 | 31 |
| 12576103 | Heparin and N-acetylcysteine for the treatment of lung injury | 🖼🧊📄§ | 2026-03-17 | 2041-03-19 | 0 | 31 |
| 12576101 | Application based nucleotides of Lactobacillus rhamnosus to prepare a composition for anti-lipogenesis | 🖼🧊📄§ | 2026-03-17 | 2044-05-29 | 0 | 31 |
| 12576102 | Methods for identifying pre-disposition to cognitive decline and agents for reducing or preventing cognitive decline, or improving cognitive ability | 🖼🧊📄§ | 2026-03-17 | 2043-03-10 | 0 | 31 |
| 12576092 | Pharmaceutical suspensions for bismuth subsalicylates | 🖼🧊📄§ | 2026-03-17 | 2043-04-19 | 0 | 31 |
| 12576090 | Oral brexanolone compositions and methods of preparation and use | 🖼🧊📄§ | 2026-03-17 | 2044-11-18 | 0 | 31 |
| 12576096 | Topical, isotonic compositions for genital use | 🖼🧊📄§ | 2026-03-17 | 2041-06-09 | 0 | 31 |
| 12576088 | Methods for enhancing cytotoxic cancer therapy through inhibition of ATG4B | 🖼🧊📄§ | 2026-03-17 | 2043-09-15 | 0 | 31 |
| 12576089 | Platelet count-agnostic methods of treating myelofibrosis | 🖼🧊📄§ | 2026-03-17 | 2044-03-12 | 0 | 31 |
| 12576084 | Methods for treating testicular and ovarian adrenal rest tumors | 🖼🧊📄§ | 2026-03-17 | 2045-01-31 | 0 | 31 |
| 12576082 | METTL16 inhibitors and uses thereof | 🖼🧊📄§ | 2026-03-17 | 2040-08-20 | 0 | 31 |
| 12576080 | Use of varenicline for treating ocular conditions | 🖼🧊📄§ | 2026-03-17 | 2045-04-03 | 0 | 31 |
| 12576076 | Use of HSP70 as a regulator of enzymatic activity | 🖼🧊📄§ | 2026-03-17 | 2044-02-19 | 0 | 31 |
| 12576078 | Compounds and combinations thereof for treating neurological and psychiatric conditions | 🖼🧊📄§ | 2026-03-17 | 2045-04-17 | 0 | 31 |
| 12576012 | Surface-modified zinc oxide particles, dispersion solution, and cosmetic | 🖼🧊📄§ | 2026-03-17 | 2040-04-30 | 0 | 31 |
| 12576018 | Active agents for skin and hair care with sensory modifying properties | 🖼🧊📄§ | 2026-03-17 | 2039-02-04 | 0 | 31 |